TC-G 24 treatment inhibited c-Myc and Mcl-1 downregulation by gilteritinib and AZD1208 cotreatment in Ba/F3-ITD and MV4-11 cells and FLT3-ITD AML primary patient blasts (Fig. 7C and D), demonstrating that c-Myc and Mc-1 downregulation by cotreatment results at least in part from GSK-3β activation. The gene discussed is MYC; the disease is acute myeloid leukemia.